IceCure Medical Receives FDA Approval For Study Design For ChoICE Trial Post-Market Study; Participant Enrollment Expected To Start In H2

IceCure Medical Ltd. (NASDAQ:ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that the U.S. Food and Drug Administration ("FDA") has approved the study design for the "ChoICE Trial Post-Market Study," the Company's post-marketing study for ProSense® in the treatment of low-risk breast cancer (the "Study"). Patient enrollment is expected to commence in the second half of 2026, with at least 80 patients expected to be enrolled in the first year of the Study.